6533b828fe1ef96bd1288f74
RESEARCH PRODUCT
One-step diagnosis strategy together with multidisciplinary telematics referral perform an effective approach for identifying and treating patients with active Hepatitis C infection.
Enrique Ortega GonzálezPurificación Rubio CuevasMiguel García-deltoroNeus Gómez-muñozMoisés Diago MadridMiriam TorrecillasMaría Dolores OceteConcepción Gimeno Cardonasubject
MaleCare processmedicine.medical_specialtyReferralHepatitis C virusSpecialties of internal medicineViremiaHepacivirusmedicine.disease_causeAntiviral AgentsSerologyMultidisciplinary approachInterquartile rangeInternal medicineHCV-cAgmedicineTelematics referralHumansOne-stepViremiaActive hepatitisHepatologyHepatitis C virusbusiness.industryTwo-stepGeneral MedicineHepatitis C Antibodiesmedicine.diseaseHepatitis CTelemedicineRC581-951FemaleHepatitis C Antigensbusinessdescription
Abstract Introduction and objectives Implementation of a one-step strategy for diagnosis of active Hepatitis C virus (HCV) infection would encourage the early diagnosis and reduce the time to access antiviral treatments. The aim of this study was to evaluate the impact of a HCV one-step diagnosis compared to the traditional two-step protocol in terms of the time required for patients to be seen by specialists and the time taken to start antiviral treatment. Material and methods A comparative study was carried out to assess two diagnostic algorithms (one-step and two-step) for active HCV infection. Serological markers were quantified using the same serum sample to determine both anti-HCV antibodies (HCV-Ab) and HCV core antigen (HCV-cAg) by Architect i2000 SR kit. In this period, a multidisciplinary procedure was started for telematics referral of viremic patients. Results One-step approach reduced the time required for patient HCV diagnosis, referral to a specialist, access to treatment, and eliminated the loss of patients to follow-up. Significant differences were observed between one-step and two-step diagnosis methods in the time required for patients to be seen by a specialist (18 days [Interquartile range (IQR) = 14–42] versus 107 days [IQR = 62–148]) and for the initiation of treatment (54 days [IQR = 43–75] versus 200 days [IQR = 116–388]), mainly for patients with advanced fibrosis (35 days [IQR = 116–388] versus 126 days [IQR = 152–366]). Conclusions Use of HCV-cAg has proven to be a useful tool for screening patients with active hepatitis C. The development of a multidisciplinary protocol for the communication of results improved the efficiency of the care process.
year | journal | country | edition | language |
---|---|---|---|---|
2021-02-02 | Annals of hepatology |